BOTHELL, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that data from a phase I single-agent clinical trial of brentuximab vedotin (SGN-35) will be published in the November 4, 2010 issue of the New England Journal of Medicine. The trial was designed to assess the safety and determine the maximum tolerated dose (MTD) of brentuximab vedotin in patients with CD30-positive hematologic malignancies, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Secondary endpoints included evaluation of antitumor activity, pharmacokinetics and immunogenicity. Brentuximab vedotin is a novel antibody-drug conjugate (ADC) targeting CD30, a marker for a number of malignancies including Hodgkin lymphoma and ALCL.
